Checkpoint Therapeutics Inc (NASDAQ: CKPT) on Tuesday, plunged -5.75% from the previous trading day, before settling in for the closing price of $3.13. Within the past 52 weeks, CKPT’s price has moved between $1.38 and $4.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -46.76% annually for the last half of the decade. The company achieved an average annual earnings per share of 72.34%. With a float of $35.94 million, this company’s outstanding shares have now reached $45.10 million.
In an organization with 23 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -45168.08%, operating margin of -79817.02%, and the pretax margin is -98868.09%.
Checkpoint Therapeutics Inc (CKPT) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Checkpoint Therapeutics Inc is 26.39%, while institutional ownership is 22.05%. The most recent insider transaction that took place on Feb 10 ’25, was worth 32,543. In this transaction CEO, President and Director of this company sold 10,331 shares at a rate of $3.15, taking the stock ownership to the 3,775,019 shares. Before that another transaction happened on Feb 07 ’25, when Company’s CEO, President and Director sold 9,233 for $3.41, making the entire transaction worth $31,485. This insider now owns 3,785,350 shares in total.
Checkpoint Therapeutics Inc (CKPT) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 72.34% per share during the next fiscal year.
Checkpoint Therapeutics Inc (NASDAQ: CKPT) Trading Performance Indicators
Checkpoint Therapeutics Inc (CKPT) is currently performing well based on its current performance indicators. A quick ratio of 0.29 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2881.20.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.44, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.26 in one year’s time.
Technical Analysis of Checkpoint Therapeutics Inc (CKPT)
Let’s dig in a bit further. During the last 5-days, its volume was 0.55 million. That was inferior than the volume of 0.82 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 17.94%. Additionally, its Average True Range was 0.23.
During the past 100 days, Checkpoint Therapeutics Inc’s (CKPT) raw stochastic average was set at 33.76%, which indicates a significant increase from 1.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.06% in the past 14 days, which was higher than the 76.10% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.32, while its 200-day Moving Average is $2.73. However, in the short run, Checkpoint Therapeutics Inc’s stock first resistance to watch stands at $3.14. Second resistance stands at $3.32. The third major resistance level sits at $3.42. If the price goes on to break the first support level at $2.85, it is likely to go to the next support level at $2.75. Assuming the price breaks the second support level, the third support level stands at $2.57.
Checkpoint Therapeutics Inc (NASDAQ: CKPT) Key Stats
Market capitalization of the company is 144.06 million based on 48,833K outstanding shares. Right now, sales total 100 K and income totals -51,850 K. The company made 40 K in profit during its latest quarter, and -6,670 K in sales during its previous quarter.
